Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
IND. SWIFT ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IND. SWIFT Mar-23 |
ADCOCK INGRAM Jun-14 |
IND. SWIFT/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 15 | 314 | - | |
Low | Rs | 7 | 226 | - | |
Sales per share (Unadj.) | Rs | 75.9 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 4.8 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 10.1 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -130.1 | 73.3 | - | |
Shares outstanding (eoy) | m | 54.16 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.1 | 2.9 | 4.8% | |
Avg P/E ratio | x | 2.2 | -11.5 | -19.1% | |
P/CF ratio (eoy) | x | 1.0 | -13.9 | -7.5% | |
Price / Book Value ratio | x | -0.1 | 3.7 | -2.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 572 | 45,603 | 1.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 637 | 2,862 | 22.3% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,110 | 15,761 | 26.1% | |
Other income | Rs m | 119 | 110 | 107.4% | |
Total revenues | Rs m | 4,228 | 15,872 | 26.6% | |
Gross profit | Rs m | 1,026 | -2,731 | -37.6% | |
Depreciation | Rs m | 287 | 680 | 42.1% | |
Interest | Rs m | 598 | 427 | 140.0% | |
Profit before tax | Rs m | 260 | -3,728 | -7.0% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 233 | 0.0% | |
Profit after tax | Rs m | 260 | -3,971 | -6.6% | |
Gross profit margin | % | 25.0 | -17.3 | -144.1% | |
Effective tax rate | % | 0 | -6.2 | -0.0% | |
Net profit margin | % | 6.3 | -25.2 | -25.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,734 | 11,544 | 23.7% | |
Current liabilities | Rs m | 9,363 | 6,495 | 144.2% | |
Net working cap to sales | % | -161.3 | 32.0 | -503.6% | |
Current ratio | x | 0.3 | 1.8 | 16.4% | |
Inventory Days | Days | 115 | 111 | 103.8% | |
Debtors Days | Days | 929 | 124 | 749.5% | |
Net fixed assets | Rs m | 3,758 | 6,729 | 55.9% | |
Share capital | Rs m | 108 | 73 | 148.0% | |
Net worth | Rs m | -7,047 | 12,371 | -57.0% | |
Long term debt | Rs m | 4,031 | 4,347 | 92.7% | |
Total assets | Rs m | 6,492 | 23,369 | 27.8% | |
Interest coverage | x | 1.4 | -7.7 | -18.6% | |
Debt to equity ratio | x | -0.6 | 0.4 | -162.8% | |
Sales to assets ratio | x | 0.6 | 0.7 | 93.9% | |
Return on assets | % | 13.2 | -15.2 | -87.1% | |
Return on equity | % | -3.7 | -32.1 | 11.5% | |
Return on capital | % | -28.4 | -19.8 | 143.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 730 | 1,345 | 54.3% | |
From Investments | Rs m | -293 | -413 | 71.0% | |
From Financial Activity | Rs m | -466 | 3,945 | -11.8% | |
Net Cashflow | Rs m | -29 | 4,878 | -0.6% |
Compare IND. SWIFT With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare IND. SWIFT With: HIKAL. CONCORD BIOTECH AAYUSH FOOD & HERBS EMMESSAR CHM LASA SUPERGENERICS
Asian shares rose cautiously on Friday as markets sobered up to the idea that U.S. rate cuts were most likely some time away.